|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GRPEL2 |
Gene summary for GRPEL2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GRPEL2 | Gene ID | 134266 |
| Gene name | GrpE like 2, mitochondrial | |
| Gene Alias | Mt-GrpE#2 | |
| Cytomap | 5q32 | |
| Gene Type | protein-coding | GO ID | GO:0006457 | UniProtAcc | Q8TAA5 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 134266 | GRPEL2 | HCC1_Meng | Human | Liver | HCC | 2.68e-28 | 5.10e-02 | 0.0246 |
| 134266 | GRPEL2 | HCC1 | Human | Liver | HCC | 1.13e-05 | 1.24e+00 | 0.5336 |
| 134266 | GRPEL2 | HCC2 | Human | Liver | HCC | 9.04e-06 | 2.54e+00 | 0.5341 |
| 134266 | GRPEL2 | S014 | Human | Liver | HCC | 2.93e-08 | 2.68e-01 | 0.2254 |
| 134266 | GRPEL2 | S015 | Human | Liver | HCC | 1.53e-08 | 2.92e-01 | 0.2375 |
| 134266 | GRPEL2 | S016 | Human | Liver | HCC | 2.43e-05 | 2.62e-01 | 0.2243 |
| 134266 | GRPEL2 | S027 | Human | Liver | HCC | 4.33e-04 | 3.81e-01 | 0.2446 |
| 134266 | GRPEL2 | S028 | Human | Liver | HCC | 1.99e-08 | 3.58e-01 | 0.2503 |
| 134266 | GRPEL2 | S029 | Human | Liver | HCC | 8.96e-07 | 3.61e-01 | 0.2581 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:007259422 | Liver | HCC | establishment of protein localization to organelle | 299/7958 | 422/18723 | 1.06e-32 | 6.10e-30 | 299 |
| GO:000660512 | Liver | HCC | protein targeting | 219/7958 | 314/18723 | 7.74e-23 | 1.49e-20 | 219 |
| GO:000645712 | Liver | HCC | protein folding | 160/7958 | 212/18723 | 1.07e-22 | 1.88e-20 | 160 |
| GO:000683912 | Liver | HCC | mitochondrial transport | 184/7958 | 254/18723 | 2.30e-22 | 3.83e-20 | 184 |
| GO:007265512 | Liver | HCC | establishment of protein localization to mitochondrion | 98/7958 | 120/18723 | 1.18e-18 | 1.46e-16 | 98 |
| GO:007058512 | Liver | HCC | protein localization to mitochondrion | 101/7958 | 125/18723 | 1.53e-18 | 1.86e-16 | 101 |
| GO:000662612 | Liver | HCC | protein targeting to mitochondrion | 82/7958 | 100/18723 | 4.93e-16 | 4.05e-14 | 82 |
| GO:001703811 | Liver | HCC | protein import | 140/7958 | 206/18723 | 1.12e-13 | 6.46e-12 | 140 |
| GO:199054212 | Liver | HCC | mitochondrial transmembrane transport | 78/7958 | 102/18723 | 2.73e-12 | 1.26e-10 | 78 |
| GO:007180611 | Liver | HCC | protein transmembrane transport | 47/7958 | 59/18723 | 5.82e-09 | 1.51e-07 | 47 |
| GO:006500211 | Liver | HCC | intracellular protein transmembrane transport | 41/7958 | 51/18723 | 3.41e-08 | 7.61e-07 | 41 |
| GO:00447431 | Liver | HCC | protein transmembrane import into intracellular organelle | 29/7958 | 36/18723 | 3.42e-06 | 4.49e-05 | 29 |
| GO:00301501 | Liver | HCC | protein import into mitochondrial matrix | 17/7958 | 20/18723 | 1.18e-04 | 9.87e-04 | 17 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| GRPEL2 | SNV | Missense_Mutation | c.619G>A | p.Gly207Ser | p.G207S | Q8TAA5 | protein_coding | deleterious(0.04) | probably_damaging(1) | TCGA-BH-A0BW-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | CR | |
| GRPEL2 | insertion | Nonsense_Mutation | novel | c.429_430insAAAAATCAGACAAGTTTTGTGGTCCATCTCTAGCAAC | p.Phe144LysfsTer11 | p.F144Kfs*11 | Q8TAA5 | protein_coding | TCGA-AR-A0TY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | PD | ||
| GRPEL2 | SNV | Missense_Mutation | novel | c.415A>G | p.Thr139Ala | p.T139A | Q8TAA5 | protein_coding | tolerated(0.29) | benign(0.005) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| GRPEL2 | SNV | Missense_Mutation | c.10C>T | p.Arg4Trp | p.R4W | Q8TAA5 | protein_coding | deleterious(0) | benign(0.001) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD | |
| GRPEL2 | SNV | Missense_Mutation | rs778549584 | c.34N>T | p.Arg12Trp | p.R12W | Q8TAA5 | protein_coding | tolerated(0.25) | benign(0) | TCGA-CK-5913-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GRPEL2 | SNV | Missense_Mutation | c.157N>T | p.Leu53Phe | p.L53F | Q8TAA5 | protein_coding | tolerated(0.05) | possibly_damaging(0.793) | TCGA-G4-6294-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD | |
| GRPEL2 | SNV | Missense_Mutation | novel | c.407N>G | p.Gln136Arg | p.Q136R | Q8TAA5 | protein_coding | tolerated(0.27) | benign(0.197) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| GRPEL2 | SNV | Missense_Mutation | novel | c.542N>G | p.Ile181Ser | p.I181S | Q8TAA5 | protein_coding | deleterious(0) | possibly_damaging(0.892) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| GRPEL2 | SNV | Missense_Mutation | novel | c.544N>G | p.Cys182Gly | p.C182G | Q8TAA5 | protein_coding | deleterious(0.04) | possibly_damaging(0.575) | TCGA-AJ-A3EL-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| GRPEL2 | SNV | Missense_Mutation | c.455C>T | p.Ala152Val | p.A152V | Q8TAA5 | protein_coding | tolerated(0.5) | probably_damaging(0.921) | TCGA-AX-A05S-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unspecific | Carboplatin & Paclitaxel | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |